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A B S T R A C T In this study, we analyzed the global metabolomic changes associated with Toxoplasma 
gondii infection in mice in the presence or absence of sulfadiazine sodium (SDZ) treatment. BALB/c 
mice were infected with T. gondii GT1 strain and treated orally with SDZ (250  g/ml in water) for 12 
consecutive days. Mice showed typical manifestations of illness at 20 days postinfection (dpi); by 30 
dpi, 20% had survived and developed latent infection. We used ultraperformance liquid 
chromatography-mass spectrometry to profile the serum metabolomes in control (untreated and 
uninfected) mice, acutely infected mice, and SDZ-treated and infected mice. Infection induced 
significant perturbations in the metabolism of  -linolenic acid, purine, pyrimidine, arginine, 
tryptophan, valine, glycerophospholipids, and fatty acyls. However, treatment with SDZ seemed to 
alleviate the serum metabolic alterations caused by infection. The restoration of the serum metabolite 
levels in the treated mice was associated with better clinical out- comes. These data indicate that 
untargeted metabolomics can reveal biochemical pathways associated with restoration of the 
metabolic status of T. gondii- infected mice following SDZ treatment and could be used to monitor 
responses to SDZ treatment. This study provides a new systems approach to elucidate the metabolic 
and therapeutic effects of SDZ in the context of murine toxoplasmosis.  
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Toxoplasma gondii, an obligate intracellular protozoan parasite, is highly prevalent in warm-blooded 
animals and humans (1). T. gondii comprises three clonal lineages (type I, type II, and type III) (2). 
Despite 98% genetic similarity, dramatic differences in virulence exist among strains belonging to 
these T. gondii genotypes (3). Humans acquire infection mainly by ingesting undercooked meat 
containing tissue cysts or oocysts from contaminated water (4). Acute infection with this parasite is 
mediated by the aggressive, fast-replicating, tachyzoite stage, which can cause encephalitis or 
retinochoroiditis. In addition, reactivation of the latent form (i.e., bradyzoites-containing cysts) of T. 
gondii can cause life-threatening conditions and even death in immuno- compromised individuals (5). 
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However, infection of immunocompetent individuals is generally asymptomatic and often involves 
type II or type III strains (6).  
Sulfadiazine sodium (SDZ) has been widely used to treat noncongenital cases of toxoplasmosis 
and often is used in combination with pyrimethamine (7). The mechanism of SDZ action involves 
inhibiting the enzyme dihydropteroate synthase, which is indispensable for folate biosynthesis (8). 
The clinical use of SDZ is often associated with side effects, such as nausea, diarrhea, headache, fever, 
rash, depression, and pancreatitis (9–11). The pathways underlying therapeutic and/or toxic 
properties of SDZ remain unknown but are likely related to alterations in the host metabolism. 
Therefore, understanding the underlying metabolomic changes associated with SDZ treatment is 
important.  
Global, high-throughput, metabolite profiling provides the opportunity to identify the 
metabolic pathways underlying the severity of disease, therapeutic responses to treatment, and 
derangement and restoration of metabolic homeostasis (12–15). The identification of perturbed 
biochemical pathways may lead to the recognition of specific metabolomic patterns associated with 
drug efficacy and adverse reactions (16, 17). Liquid chromatography-mass spectrometry (LC-MS)-
based metabolomic analysis has been a powerful approach used for metabolic profiling of biological 
systems in health and disease (18). Compared with NMR spectroscopy, LC-MS analysis possesses 
higher sensitivity and a broader polarity range (19–21).  
In the present study, we used high performance LC-tandem mass spectrometry (MS/MS) to 
test whether therapeutic interventions using SDZ, aimed at controlling T. gondii infection, could also 
attenuate the metabolic changes associated with T. gondii infection in mice. Our analysis revealed 
dysregulation of several metabolites involved in lipid and amino acid metabolism, with partial 




Therapeutic efficacy of SDZ in mice. Here, we determined the most effective dosage and duration of 
treatment using SDZ. As shown in Fig. 1A, infected mice that received a 12-day treatment regimen had 
a 20% survival rate. All infected mice in the untreated group died at 7 days postinfection (dpi), whereas 
control mice did not exhibit any clinical signs during the entire course of infection. Next, we studied 
whether the therapeutic effect of SDZ was dose dependent. We treated mice orally with 150, 200, 
250, or 300  g/ml SDZ 2 days after infection with T. gondii GT1 strain. As shown in Fig. 1B, oral 
administration of 250  g/ml SDZ protected 20% of infected mice for more than 1 month. A number of 
multifocally distributed tissue cysts were detected at 30 dpi (see Fig. S1 in the supplemental material).  
 
Metabolites distinguishing between treated and control mouse groups. We compared the serum 
metabolic profiles between infected, untreated, or SDZ-treated mice and healthy (control) mice. The 
collected serum samples were processed for untargeted LC-MS/MS-based metabolomic analysis as 
summarized in Fig. 2. As shown in Fig. S2, all total ion chromatograms of quality control (QC) samples 
showed no distinct peak drifts, with stable retention times. In electrospray ionization positive-ion 
(ESI ) mode and electrospray ionization negative-ion (ESI ) mode, 9,894 and 6,532 ions, respectively, 
were determined in each sample profile. After elimination of low- quality ions with relative standard 
deviation (RSD) values of  30%, 8,821 and 5,218 ions were identified in ESI  mode and ESI  mode, 
respectively. QC data were further interrogated using principal-component analysis (PCA). As shown 
in Fig. S3, all QC samples clustered closely together and there was an obvious separation between the 
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tested samples and the QC samples, which demonstrated the high stability and reproducibility of the 
LC-MS/MS analytical platform used in the present study.  
Changes in metabolite profiles in both ion modes over the duration of treatment were also 
detected using two-dimensional PCA score plots. As shown in Fig. S4, samples from different groups 
were intermixed and the score plots did not show good separation. Subsequently, score scatter plots 
for two-dimensional partial least-squares- discriminate analysis (PLS-DA) models showed satisfactory 
modeling and discriminated the treatment groups from the control group in both ESI  mode (Fig. 3A 
to C) and ESI  mode (Fig. S5A to C). Serum metabolites passing the variable importance in the 
projection (VIP) threshold (VIP of  1) and the Student t test (P   0.05) were selected as significantly 
different between the two groups. Heatmaps constructed based on significantly differentially 
abundant metabolites also showed clear separation between treatment groups and the control group 
in ESI  mode (Fig. 3D to F) and ESI  mode (Fig. S5D to F). Similarly, two-component PLS-DA models 
were constructed to discriminate the acutely infected mouse group from the other groups, achieving 
distinct separation between the corresponding groups in both ESI  mode (Fig. 4A to C) and ESI  mode 
(Fig. S6A to C). Interestingly, heatmaps constructed based on differentially abundant metabolites for 
acutely infected mice versus other groups showed clear clustering (Fig. 4D to F; also see Fig. S6D to F), 
demonstrating that the mouse serum metabolic phenotypes could be discriminated by the two-
component PLS-DA models.  
 
Temporal changes in metabolic profiles. Here, we identified differences in metabolites between 
treated and control mouse groups over the course of infection (acute, T6, T20, and T30 groups). A 
total of 3,142 differential metabolite ions (DMIs) were detected for the acutely infected versus control 
mouse groups. Among these DMIs, 870, 133, and 74 metabolite ions produced  1.2-, 4-, and 8-fold 
changes, respectively. In contrast, the expression levels of 402, 211, and 115 metabolite ions were 
decreased by >0.8-, 2-, and 4-fold, respectively (Fig. 5A). Only 13 DMIs were detected in the T6 
treatment group, indicating that SDZ temporarily maintained the metabolic homeostasis in the 
treated mice. The serum metabolic profiles in the T20 group changed significantly, compared to the 
control, and 1,805 DMIs were detected in both ion modes. The number of differentially abundant 
metabolites decreased over time as the infected mice partly restored the dysregulated metabolic state 
(T30 group versus control group).  
There were dramatic metabolic changes for the acute group versus the control group and the 
T20 group versus the control group. Of the 1,867 DMIs detected in ESI  mode, 764 were common for 
the acute group versus the control group and the T20 group versus the control group (Fig. 5B). By 
searching against mass-based metabolomic databases, the metabolite ions detected in both ESI  and 
ESI  modes were deter- mined to include glycerophospholipids, sphingolipids, quinolines, 
glycerolipids, pyrimidines, sterols, fatty acyls, acyl-carnitines, prenols, amino acids, and other organic 
compounds. As shown in Fig. 5D, “glycerophospholipids,” “fatty acyls,” and “prenol lipids” had the 
largest numbers of common metabolites identified in the acute group versus the control group and 
the T20 group versus the control group. In the ESI  mode, 599 DMIs were common in the acute group 
versus the control group and the T20 group versus the control group (Fig. 5C); “fatty acyls,” 
“glycerophospholipids,” and “benzene and substituted derivatives” were the three most enriched 
categories (Fig. 5E).  
As shown in Fig. 6, we categorized all of the annotated differentially abundant metabolites 
detected in each comparison pair. In the ESI  mode, the lipid category was the largest category in all 
three-comparison pairs, followed by organoheterocyclic compounds. Interestingly, the lipid category 
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was also the overrepresented metabolic category in ESI  mode (Fig. S7). These results indicate that 
lipid metabolism is significantly disturbed during T. gondii infection and SDZ treatment. All lipids were 
categorized based on the LIPID MAPS comprehensive classification system. In ESI  mode, 
“glycerophospholipid” was the overrepresented metabolite class among the three comparison pairs 
(Fig. S8A to C). In ESI  mode, however, “glycerophospholipid” was the most overrepresented class in 
both the acute group versus the control group and the T20 group versus the control group; for the 
T30 group versus the control group, “steroid and steroid derivatives” was the most represented class 
(Fig. S8D to F). Three amino acids, namely, arginine, tryptophan, and valine, showed periodic 
fluctuations (Fig. 7).  
 
Dysregulated metabolic pathways. As shown in Fig. 8A, more than 20 metabolic pathways were 
affected in acutely infected mice (acute group). Of these, several pathways, such as histidine 
metabolism, vitamin B6 metabolism, glutamine metabolism, and taurine and hypotaurine 
metabolism, showed lower P values and greater pathway impact. Differential metabolites involved in 
amino acid metabolism were also analyzed. As shown in Fig. 8D, histidine metabolism, tryptophan 
metabolism, and arginine and proline metabolism were the three most affected pathways. Mice in 
the T20 group also showed dramatic metabolic variations, and metabolic path- ways such as linoleic 
acid metabolism, glutamine metabolism,  -linoleic acid metabolism, and histidine metabolism were 
significantly perturbed (Fig. 8B). As shown in Fig. 8E, tryptophan metabolism, phenylalanine 
metabolism, and tyrosine metabolism were the three most affected amino acid metabolic pathways 
in the T20 group. Surviving mice in the T30 group showed improved metabolic balance, which 
correlated with improvement in the clinical manifestations. Pathways including porphyrin and 
chlorophyll metabolism, sphingolipid metabolism, and ether lipid metabolism were the most affected 
(Fig. 8C). Seven differential metabolites involved in purine metabolism were found, including N-
formylglycinamide ribonu- cleotide, glycinamide ribonucleotide, xanthine, uric acid, allantoic acid, 
adenosine, and 5-hydroxyisourate (HIU) (Fig. 9A). Among these metabolites, uric acid, allantoic acid, 
and HIU were upregulated in the acute group versus the control group and the T20 group versus the 
control group, suggesting active purine degradation. Also, pyrimidine metabolism was affected during 
toxoplasmosis and treatment. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed 
that cytosine and uridine were upregulated in the T30 group versus the control group and cytidine 
and dUMP were both downregulated in the acute group versus the control group and the T20 group 
versus the control group (Fig. 9B).  
 
DISCUSSION  
This study represents the first LC-MS/MS-based analysis of serum metabolites in mice infected with 
T. gondii in the presence or absence of SDZ treatment. Our results showed that SDZ treatment could 
ameliorate the metabolic alterations caused by T. gondii infection and might have contributed to the 
parasite differentiation from tachyzoites to bradyzoite-containing cysts.  
BALB/c mice infected with genotype II parasites develop acute signs of illness at 11 dpi and 
establish chronic infections by 21 dpi. In contrast, without pharmaceutical intervention, mice infected 
with genotype I parasites develop acute toxoplasmosis and die within 10 days. In our previous study, 
880 metabolites were altered in mice infected with genotype II T. gondii. These altered metabolites 
were involved in a range of metabolic pathways, including nucleotides, amino acids, fatty acyls, and 
central carbon metabolism intermediates (22). In the present study, genotype I parasites altered the 
abundance of 2,872 metabolites in mouse serum; most of these metabolites belonged to the category 
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of lipid or lipid derivatives. In the first week after SDZ treatment, infected mice did not show any signs 
and only 13 differential metabolite features were detected. A relapse of acute signs occurred after the 
cessation of SDZ therapy, although 20% of the mice survived. The association between the reduction 
in the number of metabolites and mouse survival suggests that the observed clinical improvement 
might be attributed to SDZ treatment and the subsequent correction of the metabolic disturbances.  
With searching against the Human Metabolome Database (HMDB), glycerophospholipids and fatty 
acyls were the overrepresented lipid classes in both ion modes. Glycerophospholipids are key 
components of the lipid bilayers in biological membranes and are involved in various signaling 
processes (23). The fatty acyls are a diverse group of molecules synthesized through chain elongation 
of an acetyl-coenzyme A (CoA) primer with malonyl-CoA, and they contribute to various biological 
processes (24). We also categorized the differential metabolites among infected, treated, and control 
groups. By comparing all mouse group pairs, lipid was found to be the most perturbed category. 
“Glycerophospholipids,” “fatty acyls,” and “prenol lipid” were the three most perturbed classes in ESI  
mode. In ESI  mode, however, “steroid and steroid derivatives” was the second largest class in a 
comparison of the T30 group versus the control group, indicating that the serum metabolome in the 
T30 group differed from those in the acute and T20 groups in both the number and type of 
metabolites.  
We also detected alterations in amino acids involved in arginine, tryptophan, and valine 
metabolism. T. gondii acquires arginine from the host, and arginine limitation significantly reduces 
parasite growth (25). The marked decline of arginine abundance in the acutely infected and T20 mouse 
groups might reflect the increased nutritional demand for arginine by the rapidly proliferating 
parasites. Interestingly, a previous study showed that arginine starvation could induce cyst-like 
structures (26), which is consistent with our finding of parasite cysts in the T30 mouse group. The 
essential biological functions of amino acids make them possible targets for host-mediated disease 
therapy. For example, arginine deiminase, an arginine-degrading enzyme, was shown to be effective 
in the treatment of arginine-auxotrophic tumors (27). Tryptophan (Trp) levels were also decreased in 
acutely infected mice, which is consistent with a previous study (28). Indoleamine 2,3-dioxygenase 
(IDO) is an important enzyme in the kynurenine pathway. T. gondii growth can be reduced by Trp 
degradation into kynurenine, through induction of IDO mediated by gamma interferon (29). 
Kynurenine is an aryl hydrocarbon receptor agonist and is important for the expansion of Treg cells 
(30), which play an important role in maintaining immune homeostasis by actively suppressing the 
proinflammatory response. Compared with the acutely infected group, mice in the T20 group showed 
slightly higher levels of Trp, which might account for the improved survival rate.  
To obtain more insight into the metabolic changes, we performed pathway analysis of the 
serum metabolome.  -Linolenic acid is an essential nutrient that functions as a substrate for the 
synthesis of long-chain fatty acids (31). The  -linolenic acid pathway was severely compromised in 
acutely infected mice, which was related to the reduced appetite of infected mice. This finding agrees 
with the previous observation that T. gondii infection of mice significantly influenced the linolenic acid 
pathway 11 days after infection with cysts of the genotype II PRU strain. In the T20 group, valine, 
leucine and isoleucine degradation and biosynthesis pathways were significantly perturbed. Valine, 
leucine, and isoleucine represent a potential source of energy and serve as building blocks for the 
synthesis of other amino acids (32). Trp metabolism is essential for normal growth in young animals 
and is necessary for the maintenance of nitrogen equilibrium in mature animals (33). The number of 
differential metabolites involved in Trp metabolism was considerable. These findings indicate that 
nitrogen metabolism of mice could be disturbed during acute infection and in the T20 group. Purine 
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metabolism and pyrimidine metabolism were significantly affected in the T30 group. Cytidine and 
cytosine, two intermediates in pyrimidine metabolism, were upregulated in T30 group, pointing to 
increased DNA repair activities.  
In conclusion, we performed the first untargeted LC-MS/MS-based metabolomic profiling of 
serum from mice infected with T. gondii in the presence or absence of SDZ treatment. Multivariate 
statistical analysis showed different serum metabolites for the infected and treated versus untreated 
groups, indicating that SDZ treatment influences the metabolism of T. gondii-infected mice. Changes 
in the metabolite levels in SDZ- treated mice over time revealed metabolites associated with clinical 
improvement, suggesting that the therapeutic efficacy of SDZ against T. gondii infections may have a 
metabolic basis. These results improved our understanding of the systemic metabolic response of T. 
gondii-infected mice treated with SDZ. Future studies incorporating metabolomic approaches will be 
of great value in guiding future preclinical investigations concerning pharmacotherapy of 
toxoplasmosis.  
 
MATERIALS AND METHODS  
Ethics statement. The study was approved by the Animal Ethics Committee of Lanzhou Veterinary 
Research Institute, Chinese Academy of Agriculture Sciences (permit no. LVRIAEC2016-007). All 
experiments were performed strictly according to the requirements of the Animal Ethics Procedures 
and Guidelines of the People’s Republic of China.  
 
Chemicals. Sulfadiazine sodium salt (purity of >98%) was purchased from Sigma-Aldrich Co. (St. 
Louis, MO, USA). MS-grade water, acetonitrile, and methanol were purchased from Fischer Scientific 
(Morris Plains, NJ, USA). All other chemicals used were of the highest grade commercially available.  
 
Mice and parasite. Eight-week-old female BALB/c mice were purchased from the experimental animal 
center of Lanzhou Veterinary Research Institute, Chinese Academy of Agriculture Sciences, People’s 
Republic of China. All mice were fed and maintained under specific-pathogen-free conditions. All mice 
had free access to food and water and were kept in a temperature-controlled room (22   0.5°C) with 
a seminatural light/dark cycle of 12 h/12 h. Mice were acclimated for 2 weeks before being used in 
the experiment. The T. gondii type I GT1 strain was used in this study. The tachyzoite stage of this 
parasite strain was maintained by serial passage in confluent monolayers of human foreskin 
fibroblasts (HFFs) (ATCC CRL-2522), which were cultured in Dulbecco’s modified Eagle’s medium 
(Gibco) supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 2 mM L-glutamine, 100 
U/ml penicillin, and 10  g/ml streptomycin (34). All parasites and HFFs were maintained at 37°C in a 
5% CO2 incubator.  
 
Drug efficacy studies with SDZ. Here, two experiments were performed in order to determine the 
most effective treatment regimen for SDZ. In the first experiment, we sought to determine the optimal 
duration of SDZ treatment that would enhance the animal survival rate. Forty mice were 
intraperitoneally (i.p.) infected with 103 T. gondii GT1 tachyzoites. After 2 days, infected mice were 
randomly allocated into four groups (10 mice/group). There was one vehicle-treated control group 
(sham treated with phosphate-buffered saline [PBS] only) and three treated groups (i.e., orally treated 
for 8, 10, or 12 days with 250  g/ml SDZ diluted in filtered drinking water). The treatment dosage of 
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250  g/ml per day was chosen based on a previous study (35). In the second experiment, we set out 
to examine whether the therapeutic effect of SDZ was dose dependent. Briefly, 50 BALB/c mice were 
randomly assigned to five groups (10 mice/group). All mice were i.p. infected as described above. 
After 2 days, one group received PBS only (vehicle control) and four groups were treated orally with 
150, 200, 250, or 300  g/ml SDZ. The deaths of mice were recorded daily, and the survival curve was 
produced using GraphPad Prism software.  
 
Sample collection and metabolite extraction. Serum was collected from the vehicle-treated control 
mouse group (control group) and the untreated plus infected group (acute group). Serum was 
collected from treated mouse groups at 6, 12, and 30 dpi (T6, T20, and T30 groups, respectively). The 
blood samples from all mouse groups were prepared as described previously (36). Briefly, blood was 
collected rapidly into Eppendorf tubes by retroorbital bleeding and was allowed to clot for 2 h, 
followed by centrifugation at 3,000   g for 10 min at 4°C. Supernatants were collected, frozen in liquid 
N2 for 3 min, and transferred to a  80°C freezer until analysis. The metabolite extraction was 
performed as described previously (22). Briefly, serum samples were gradually defrosted by placing 
the tubes initially at  20°C for 30 min and then at 4°C. Aliquots (40  l) of serum samples were mixed 
with 120  l methanol (1:3 [vol/vol]) for 1 min. The mixture was kept at  20°C for 30 min, followed by 
centrifugation at 4,000   g for 20 min at 4°C. About 20  l of the supernatant was transferred into a 
new tube and mixed with 180  l methanol before LC separation.  
 
LC-MS-based metabolomics. Metabolomic analysis was performed using a 2777C ultraperformance 
liquid chromatography (UPLC) system (Waters, Manchester, UK) coupled to a Synapt G2-XS 
quadrupole time of flight (TOF) MS system (Waters) equipped with an electrospray ionization (ESI) 
source. The separation of all samples was performed with a Waters Acquity UPLC BEH C18 column 
(100 by 2.1 mm; particle size, 1.8  m). A gradient elution program was run for chromatographic 
separation with mobile phase A (water) and mobile phase B (acetonitrile), as follows: 0 to 2 min, 100% 
mobile phase A; 2 to 12 min, 100% mobile phase A to 0% mobile phase A; 12 to 14 min, 0% mobile 
phase A; 14 to 15 min, 0% mobile phase A to 100% mobile phase A. The injection volume was 10  l, 
and the flow rate was set as 0.4 ml/min.  
 
The mass spectrometer was operated in both positive-ion and negative-ion modes, with the following 
parameters: capillary, 1 kV (ESI ) or 2 kV (ESI ); sampling cone, 40 V; source temperature, 120°C; 
desolvation temperature, 500°C; desolvation gas, 800 liters/h (ESI ); cone gas, 50 liters/h; source 
offset, 80; TOF acquisition mode, sensitivity (ESI ) or sensitivity (ESI ); acquisition method, continuum 
MSE; TOF mass range, 100 to 1,200 Da; scan time, 0.1 s; collision energy function 2, trap CE ramp of 
19 to 45 eV.  To evaluate the stability and reproducibility of the LC-MS analytical platform during data 
acquisition, QC samples were analyzed. The QC samples were prepared by mixing equal volumes (10 
 l) from each serum sample as they were aliquoted for analysis. This pooled sample was used to 
provide a “mean” profile representing all analytes obtained during the analysis. The pooled QC sample 
was run 10 times at the beginning of the analysis and before and after each batch of 10 serum samples.  
 
Data processing, mass spectral identification, and statistical analyses. Raw metabolomic data sets 
were imported into the Progenesis QI 2.0 software package (Waters) for data processing, including 
untargeted peak detection, peak alignment, peak grouping, normalization, and integration. The 
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normalized peak data were further processed using metaX software (37). Metabolites with RSD of 
 30% in QC pools were filtered out. Multivariate statistical analyses, including PCA and PLS-DA, were 
applied to identify outliers and to maximize the separation between groups, respectively (38). 
Differentially abundant metabolites that discriminated between test groups and the healthy controls 
were identified by VIP, with a threshold of  1, in the PLS-DA model. For each metabolite, the statistical 
significance of the difference between the means of two groups was determined using PCA. PLS-DA 
was used to distinguish two groups for each comparable group. We used the prcomp function in the 
R software package to perform PCA. The scores for Q2 (Q2Y, indicating the model performance) and 
R2 (R2Y, indicating how much of the variation within a data set can be explained by the various 
components of the model) were used to evaluate the quality and performance of the PLS-DA model. 
The data were converted to log2 values, and the Pareto scaling method was used for data scaling prior 
to analysis with the PLS-DA model (39, 40). The VIP threshold for the first two principal components 
of the multivariate PLS-DA model, as determined by metaX software, combined with the fold change 
and the P value from single-variable analysis, was used to identify the differentially expressed 
metabolites, which were presented as a volcano plot. The screening conditions were VIP of  1, change 
of  1.2-fold or  0.8-fold, and P value of  0.05. The cluster analysis used the pheatmap function in the 
pheatmap package in R. The cluster data were converted to log2 values before being used in the 
cluster analysis. Student’s t test was used, and corrected P values (q values) of  0.05 were deemed 
statistically significant.  
 
Metabolite annotation and pathway analysis. Metabolite identification was performed by matching 
the exact molecular mass data (m/z) of the samples against METLIN (http://metlin.scripps.edu) and 
HMDB (http://www.hmdb.ca), with an accuracy of 10 ppm (41, 42). To further increase the confidence 
in the identification and to reduce the number of false hits, MS/MS spectra for the characteristic ions 
and fragmentation patterns of the compound were matched against the reference spectra in HMDB, 
METLIN, and mzcloud (http://www.mzcloud.org) (43). Quantitatively different metabolites were 
mapped to the reference pathway in the online KEGG database (http://www.genome.jp/kegg). 
Significantly enriched pathways were assessed on the basis of the false-discovery-rate-adjusted 
hypergeometric test statistic (P values of  0.05).  
 
Data availability. The metabolomic data have been submitted to the MetaboLights database under 
accession number MTBLS852. The full data set is also available from Chun-Xue Zhou upon request 
(zhouchunxue23@163.com).  
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FIG 1 Survival rates for control, untreated, and SDZ-treated mice plotted over time following T. gondii 
infection. (A) Survival of T. gondii-infected mice increased as the treatment duration increased. (B) A 







































FIG 2 Schematic diagram of the experimental design. Serum samples from control untreated mice and 



















FIG 3 Discrimination between treated and control mice based on ESI+-mode-derived metabolic 
phenotypes of serum. (A to C) PLS-DA score plots for the T6 group versus the control group (A), the 
T20 group versus the control group (B), and the T30 group versus the control group (C). (D to F) 
Heatmaps of the differential metabolites for the T6 group versus the control group (D), the T20 group 


















FIG 4 Discrimination between the control group, the T6 group, and the T20 group versus acutely 
infected (acute) mice based on ESI+-mode-derived serum metabolic profiles. (A to C) PLS-DA score 
plots for control versus acutely infected mice (A), the T6 group versus acutely infected mice (B), and 
the T20 group versus acutely infected mice (C). (D to F) Heatmaps of the top differential metabolites 
for control versus acutely infected mice (D), the T6 group versus acutely infected mice (E), and the T20 















FIG 5 Global view of the temporal metabolic expression profiles during SDZ treatment. (A) Statistics 
for differentially expressed metabolites among samples. FC, fold change; Con, control. (B and C) Venn 
diagram analysis of differentially abundant metabolites between SDZ-treated (T20) and untreated 
acutely infected mice versus control (PBS-treated) mice. The numbers in the overlapping part of the 
circles represent common differentially abundant metabolites between the mouse groups in the ESI+ 
mode (B) and ESI– mode (C). (D) Top 10 enriched metabolite classes common for the acute group 
versus the control group and the T20 group versus the control group in ESI+ mode. (E) Top 10 enriched 
metabolite classes common for the acute group versus the control group and the T20 group versus 
the control group in ESI– mode. The x axis represents the number of metabolites for the chemical 




















FIG 6 Summary statistics for the annotated differential metabolites identified among different groups 
in ESI  mode. (A) Ten largest categories for mice in the acute infection group versus the control group. 
(B) Ten largest categories for the T6 group versus the control group. (C) Eight largest categories for 
the T30 group versus the control group. The numbers in the Venn diagrams represent the numbers of 



























FIG 7 Amino acid fluctuations during SDZ treatment. The x axis represents the mouse experimental 
groups and the y axis represents the relative abundance of the corresponding amino acids. *, P <0.05; 




















FIG 8 Perturbed metabolic pathways in T. gondii infection and SDZ treatment. (A to C) Pathway impacts 
resulting from the differential metabolites determined using MetaboAnalyst 3.0. Small P values and 
high pathway impact factors indicate that the pathway is greatly influenced. (A) Acute group versus 
the control group. (B) T20 group versus the control group. (C) T30 group versus the control group. (D 
to F) Distribution of differential metabolites involved in amino acid metabolism. (D) Acute group 
versus the control group. (E) T20 group versus the control group. (F) T30 group versus the control 
group. The numbers in the Venn diagrams represent the numbers of the differential metabolites 







FIG 9 Differential metabolites involved in purine metabolism (A) or pyrimidine metabolism (B). AICAR, 
aminoimidazolecarboxamide ribotide; AIR, 5-aminoimidazole ribonucleotide; CAIR, 4-carboxy 
aminoimidazole ribonucleotide; FAICR, formylaminoimidazole carboxamide ribotide; FGAM, 
formylglycinamidine ribonucleotide; FGAR, N-formylglycinamide ribonucleotide; GAR, glycinamide 
ribonucleotide; HIU, 5-hydroxyisourate; OMP, orotidine monophosphate; PRA, phosphoribosylamine; 
PRPP, phosphoribosyl pyrophosphate; SAICAR, succinylaminoimidazole carboxamide ribotide.  
 
